U.S. drug prices are rising again, but this isn’t chaos—it’s by design. Americans pay roughly three times what Europeans do because the U.S. market funds global pharmaceutical R&D. Companies hike list prices broadly, cut select Medicare or negotiated-program prices strategically, and rely on opaque discounts behind the scenes.
